Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Subscribe to see Becton, Dickinson and Company (BD)’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Becton, Dickinson and Company (BD) is a medical devices company headquartered in Franklin Lakes, United States, founded in 1897. It is publicly listed (BDX) with a market capitalisation of $50.4B. Xcout tracks 24 named people at Becton, Dickinson and Company (BD), including Thomas E. Polen Jr. (President, Chief Executive Officer & Chairman). Xcout recorded 1,001 job postings from Becton, Dickinson and Company (BD) in the last 90 days, naming tools such as SAP, Salesforce, Power BI.
18 more named people on record for Becton, Dickinson and Company (BD), with roles, board committees and tenure — see the full roster →
Xcout recorded 1,001 job postings from Becton, Dickinson and Company (BD) in the last 90 days, from a hiring record Xcout has kept since May 2026.
The weekly hiring trend, the roles and locations behind it and all 20 tools — see Becton, Dickinson and Company (BD)'s hiring signals →
Based on 603 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 168 enterprise healthcare companies.
This describes a hiring pattern — how often Becton, Dickinson and Company (BD)’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.